RenovoRx, Inc.
RNXTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $43,000 | — | — | — | — |
| Operating income | −$12.5M | −$11.0M | −$11.4M | −$9.9M | −$5.7M | −$3.2M |
| Net income | −$11.2M | −$8.8M | −$10.2M | −$9.9M | −$6.3M | −$3.8M |
| Total assets | $8.1M | $8.1M | $1.5M | $7.3M | $16.3M | $1.9M |
| Total liabilities | $2.7M | $3.6M | $4.5M | $1.1M | $938,000 | $4.1M |
| Equity | $5.4M | $4.5M | −$3.0M | $6.2M | $15.3M | −$14.7M |
| EPS (diluted) | $-0.32 | $-0.40 | $-0.99 | $-1.09 | $-1.21 | — |
| Shares out. | 36.5M | 16.9M | 9.1M | 9.0M | 8.9M | 2.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1114.0%
- Net margin
- −994.5%
- Return on equity
- −206.0%
- Return on assets
- −138.0%
- Return on capital (ROCE)
- −204.0%
- Liabilities / assets
- 33.0%
- Debt / equity
- 0.49×
- Book value / share
- $0.15
- Revenue growth (YoY)
- 2511.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -28.17distress
- Accruals / assets
- −2.4%clean
- Beneish M-Score
- 19.23elevated
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Hirschman OrinPassive (13G)Apr 27, 2026
- Awm Investment Company, Inc.Passive (13G)Nov 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 384,039 | 1.4 | -24.1% |
| Apr 30, 2026 | 505,892 | 1.6 | +7.4% |
| Apr 15, 2026 | 470,946 | 1.6 | -20.8% |
| Mar 31, 2026 | 594,804 | 1.0 | -3.7% |
| Mar 13, 2026 | 617,404 | 2.0 | +41.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Results of operations · Other material eventMar 30, 2026
- Director / officer changeMar 27, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventMar 23, 2026
- Director / officer change · Other material eventFeb 6, 2026
- Delisting / listing-standard noticeJan 2, 2026
- Entered a material agreementNov 14, 2025
- Results of operations · Other material eventNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.